Urethral Carcinoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma (NCT01282463) | Eli Lilly and Company | 2011-04-01 |
| Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer (NCT01526486) | Emory University | 2009-06-01 |
Track Urethral Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.